The integration of artificial intelligence into cancer treatment is not merely a futuristic vision but a rapidly approaching reality. With the emergence of agentic AI—intelligent systems capable of autonomously performing tasks—oncologists are gaining unprecedented support in clinical decision-making. This advancement is particularly evident in tumor board meetings, where multidisciplinary teams gather to discuss complex cancer cases. By leveraging the combined expertise of various specialists, these meetings have long emphasized that collective reasoning enhances treatment strategies.
As AI technology evolves, the potential for these systems to deliver contextualized treatment options is expanding. AI agents are being designed to serve essential roles as context delivery machines, processing extensive clinical data, modeling drug-tumor interactions, and scanning existing literature for similar cases. Their incorporation into oncological practices promises to elevate personalized care for patients.
Dr. Tae Hyun Hwang, a leading figure in this field, represents the forefront of AI-driven oncology research. As the endowed director of AI research at Vanderbilt University Medical Center and the founding director of the Molecular AI Initiative, Hwang's lab has received the AACR Innovation and Discovery Grant for its pioneering work on AI analytics in gastric cancer. He notes that rapid advancements in AI technology have allowed his team to enhance their analytical capabilities, ultimately aiming to provide oncologists with the most relevant treatment guidance across diverse cancer types.
The Orchestra of Agentic AI
At the AACR Annual Meeting in 2026, Dr. Hwang unveiled his project, which involves a sophisticated orchestration of multiple agentic AI platforms. This system aims to streamline the decision-making process for oncologists by offering a structured approach to analyzing patient tumor data. He remarks, “A year before the Annual Meeting in San Diego, this idea did not exist.” The rapid growth of AI has enabled his team to develop a comprehensive suite of tools that assist in clinical decision-making.
The first component, Cartographer, utilizes stained histopathology images, integrating tumor biology insights with established treatment protocols, off-label uses, and investigational therapies currently in clinical trials. This approach ensures that oncologists have a thorough view of potential treatment options tailored to individual patients.
Following Cartographer is Witness, which monitors drug interactions in patient-derived models, including cells, organoids, and live tissue. This platform captures critical data on drug uptake and cytotoxic effects, providing visual feedback on how candidate therapies perform in real-time scenarios. Such insights are invaluable for clinicians seeking to understand the efficacy of potential treatments before they are administered.
Next in the sequence is Scout, which models the expected metastatic trajectory of tumors while evaluating how selected therapies may alter this progression. The ability to predict and understand these dynamics is crucial for developing effective treatment plans.
The Terrain of Cancer Treatment
The final platform, Terrain, focuses on the structural aspects of the tumor itself. Understanding the tumor’s architecture is essential for determining the effectiveness of various treatments. As Dr. Hwang states, “Knowing how the tumor is structured has critical implications for treatment’s effectiveness, and Terrain aims to provide an understanding of that up front.” By identifying potential complications, such as abnormal vasculature, clinicians are better equipped to create effective strategies before encountering unforeseen challenges.
The collaborative effort of these AI platforms marks a significant shift in how oncologists approach patient care. The capabilities offered by agentic AI not only enhance the accuracy of treatment recommendations but also empower oncologists to act with greater confidence in their clinical decisions. As these technologies continue to advance, the future of oncology looks set to embrace an era where AI and human expertise work together to improve patient outcomes.
The intersection of agentic AI and oncology is paving the way for a new standard of care that prioritizes contextual understanding and collaborative decision-making. As this field evolves, the focus will remain on refining these tools to meet the complex needs of cancer treatment effectively.
The stories that move AI & crypto markets — before the market reacts.
Free. 7am ET. Five stories. 62,400 readers.
